A three-gene signature marks the time to locoregional recurrence in luminal-like breast cancer.

ABSTRACT:

Background

Gene expression profiling (GEP)-based prognostic signatures are being rapidly integrated into clinical decision making for systemic management of breast cancer patients. However, GEP remains relatively underdeveloped for locoregional risk assessment. Yet, locoregional recurrence (LRR), especially early after surgery, is associated with poor survival.

Patients and methods

GEP was carried out on two independent luminal-like breast cancer cohorts of patients developing early (≤5 years after surgery) or late (>5 years) LRR and used, by a training and testing approach, to build a gene signature able to intercept women at risk of developing early LRR. The GEP data of two in silico datasets and of a third independent cohort were used to explore its prognostic value.

R

SUBMITTER: Chiodoni C 

PROVIDER: S-EPMC10485389 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature